This is the first study to show that hydroxychloroquine (plaquenil, HCQ) use is associated with lower odds of having persistently positive lupus anticoagulant (LAC) and/or antiphospholipid antibodies. (aPL). The Journal of Rheumatology, Vol. 40, No. 1 30-33 August 1, 2012. (Also see: Antiphospholipid, Lupus Treatments, and Antimalarials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.